Literature DB >> 8517720

Biochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli.

P Nordmann1, S Mariotte, T Naas, R Labia, M H Nicolas.   

Abstract

A clinical isolate of Enterobacter cloacae, strain NOR-1, exhibited resistance to imipenem and remained susceptible to extended-spectrum cephalosporins. Clavulanic acid partially restored the susceptibility of the strain to imipenem. Two beta-lactamases with isoelectric points (pI) of 6.9 and > 9.2 were detected in strain E. cloacae NOR-1; the higher pI corresponded to AmpC cephalosporinase. Plasmid DNA was not detected in E. cloacae NOR-1 and imipenem resistance could not be transferred into Escherichia coli JM109. The carbapenem-hydrolyzing beta-lactamase gene was cloned into plasmid pACYC184. One recombinant plasmid, pPTN1, harbored a 5.3-kb Sau3A fragment from E. cloacae NOR-1 expressing the carbapenem-hydrolyzing beta-lactamase. This enzyme (pI 6.9) hydrolyzed ampicillin, cephalothin, and imipenem more rapidly than it did meropenem and aztreonam, but it hydrolyzed extended-spectrum cephalosporins only weakly and did not hydrolyze cefoxitin. Hydrolytic activity was partially inhibited by clavulanic acid, sulbactam, and tazobactam, was nonsusceptible to chelating agents such as EDTA and 1,10-o-phenanthroline, and was independent of the presence of ZnCl2. Its relative molecular mass was 30,000 Da. Induction experiments concluded that the carbapenem-hydrolyzing beta-lactamase biosynthesis was inducible by cefoxitin and imipenem. Subcloning experiments with HindIII partial digests of pPTN1 resulted in a recombinant plasmid, designated pPTN2, which contained a 1.3-kb insert from pPTN1 and which conferred resistance to beta-lactam antibiotics. Hybridization studies performed with a 1.2-kb HindIII fragment from pPtN2 failed to determine any homology with ampC of E. cloacae, with other known beta-lactamase genes commonly found in members of the family Enterobacteriaceae (bla(TEM-1)) and bla(SHV-3) derivatives), and with previously described carbapenemase genes such as those from Xanthomonas maltophilia, Bacillus cereus, Bacteroides fragilis (cfiA), and Aeromonas hydrophila (cphA). This work describing the biochemical properties of a novel chromosome-encoded beta-lactamase from E. cloacae indicates that this enzyme differs from all the previously described carbapenemases. This is the first reported cloning of a carbapenem-hydrolyzing gene from a member of the family Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517720      PMCID: PMC187856          DOI: 10.1128/AAC.37.5.939

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.

Authors:  J P Quinn; E J Dudek; C A DiVincenzo; D A Lucks; S A Lerner
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

2.  Molecular cloning and DNA homology of plasmid-mediated beta-lactamase genes.

Authors:  R C Levesque; A A Medeiros; G A Jacoby
Journal:  Mol Gen Genet       Date:  1987-02

3.  The production and molecular properties of the zinc beta-lactamase of Pseudomonas maltophilia IID 1275.

Authors:  R Bicknell; E L Emanuel; J Gagnon; S G Waley
Journal:  Biochem J       Date:  1985-08-01       Impact factor: 3.857

4.  Molecular genetic analysis of cephalosporinase production and its role in beta-lactam resistance in clinical isolates of Enterobacter cloacae.

Authors:  M H Nicolas; N Honore; V Jarlier; A Philippon; S T Cole
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.

Authors:  C Yanisch-Perron; J Vieira; J Messing
Journal:  Gene       Date:  1985       Impact factor: 3.688

6.  Properties of novel beta-lactamase produced by Bacteroides fragilis.

Authors:  A Yotsuji; S Minami; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

7.  Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis.

Authors:  G J Cuchural; M H Malamy; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

8.  Biochemical properties of beta-lactamase produced by Legionella gormanii.

Authors:  T Fujii; K Sato; K Miyata; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

9.  Beta-lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila.

Authors:  K Shannon; A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

10.  Inducible cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli.

Authors:  N Honoré; M H Nicolas; S T Cole
Journal:  EMBO J       Date:  1986-12-20       Impact factor: 11.598

View more
  65 in total

1.  Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein.

Authors:  P D Stapleton; K P Shannon; G L French
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  First class a carbapenemase isolated from enterobacteriaceae in Argentina.

Authors:  Marcela Radice; Pablo Power; Gabriel Gutkind; Karina Fernández; Carlos Vay; Angela Famiglietti; Nora Ricover; Juan A Ayala
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Characterization of a Novel Putative Xer-Dependent Integrative Mobile Element Carrying the bla(NMC-A) Carbapenemase Gene, Inserted into the Chromosome of Members of the Enterobacter cloacae Complex.

Authors:  Alberto Antonelli; Marco Maria D'Andrea; Vincenzo Di Pilato; Bruno Viaggi; Francesca Torricelli; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

Review 4.  Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods.

Authors:  Roberto Viau; Karen M Frank; Michael R Jacobs; Brigid Wilson; Keith Kaye; Curtis J Donskey; Federico Perez; Andrea Endimiani; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

Review 5.  A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.

Authors:  Alain Philippon; Patrick Slama; Paul Dény; Roger Labia
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

6.  Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.

Authors:  Neil Woodford; Philip M Tierno; Katherine Young; Luke Tysall; Marie-France I Palepou; Elaina Ward; Ronald E Painter; Deborah F Suber; Daniel Shungu; Lynn L Silver; Kenneth Inglima; John Kornblum; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase.

Authors:  Jimena Alba; Yoshikazu Ishii; Kenneth Thomson; Ellen Smith Moland; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

8.  SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases.

Authors:  Anne Marie Queenan; Wenchi Shang; Paul Schreckenberger; Karen Lolans; Karen Bush; John Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

9.  Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa.

Authors:  C Dib; J Trias; V Jarlier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

Review 10.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.